Febuxostat in gout patients with hyperuricaemia and moderate-to-severe renal impairment

Trial Profile

Febuxostat in gout patients with hyperuricaemia and moderate-to-severe renal impairment

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2013

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Gout; Hyperuricaemia; Renal impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Nov 2013 New trial record
    • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 Oct 2013 Primary endpoint 'Uric-acid-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top